BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tanaka Y, Sato Y, Sasaki T. Feline coronavirus replication is affected by both cyclophilin A and cyclophilin B. J Gen Virol 2017;98:190-200. [PMID: 27902373 DOI: 10.1099/jgv.0.000663] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 D'Marco L, Puchades MJ, Romero-Parra M, Gimenez-Civera E, Soler MJ, Ortiz A, Gorriz JL. Coronavirus disease 2019 in chronic kidney disease. Clin Kidney J 2020;13:297-306. [PMID: 32699615 DOI: 10.1093/ckj/sfaa104] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
2 [DOI: 10.1101/2020.06.19.161042] [Cited by in Crossref: 30] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
3 Softic L, Brillet R, Berry F, Ahnou N, Nevers Q, Morin-Dewaele M, Hamadat S, Bruscella P, Fourati S, Pawlotsky JM, Ahmed-Belkacem A. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025). Antimicrob Agents Chemother 2020;64:e00876-20. [PMID: 32376613 DOI: 10.1128/AAC.00876-20] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
4 Raj K, Kaur K, Gupta GD, Singh S. Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19. Naunyn Schmiedebergs Arch Pharmacol 2021;394:1383-402. [PMID: 33961065 DOI: 10.1007/s00210-021-02091-5] [Reference Citation Analysis]
5 Pawlotsky JM. COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir. Clin Infect Dis 2020;71:2191-4. [PMID: 32409832 DOI: 10.1093/cid/ciaa587] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
6 Liu C, von Brunn A, Zhu D. Cyclophilin A and CD147: novel therapeutic targets for the treatment of COVID-19. Med Drug Discov 2020;7:100056. [PMID: 32835213 DOI: 10.1016/j.medidd.2020.100056] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
7 de Wilde AH, Pham U, Posthuma CC, Snijder EJ. Cyclophilins and cyclophilin inhibitors in nidovirus replication. Virology 2018;522:46-55. [PMID: 30014857 DOI: 10.1016/j.virol.2018.06.011] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
8 Li Y, Yang L. Cyclophilin A represses reactive oxygen species generation and death of hypoxic non-small-cell lung cancer cells by degrading thioredoxin-interacting protein. Cell Cycle 2022. [PMID: 35579671 DOI: 10.1080/15384101.2022.2078615] [Reference Citation Analysis]
9 Ma-Lauer Y, Zheng Y, Malešević M, von Brunn B, Fischer G, von Brunn A. Influences of cyclosporin A and non-immunosuppressive derivatives on cellular cyclophilins and viral nucleocapsid protein during human coronavirus 229E replication. Antiviral Res 2020;173:104620. [PMID: 31634494 DOI: 10.1016/j.antiviral.2019.104620] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
10 de Wilde AH, Zevenhoven-Dobbe JC, Beugeling C, Chatterji U, de Jong D, Gallay P, Szuhai K, Posthuma CC, Snijder EJ. Coronaviruses and arteriviruses display striking differences in their cyclophilin A-dependence during replication in cell culture. Virology 2018;517:148-56. [PMID: 29249267 DOI: 10.1016/j.virol.2017.11.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
11 Dittmar M, Lee JS, Whig K, Segrist E, Li M, Kamalia B, Castellana L, Ayyanathan K, Cardenas-Diaz FL, Morrisey EE, Truitt R, Yang W, Jurado K, Samby K, Ramage H, Schultz DC, Cherry S. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2. Cell Rep 2021;35:108959. [PMID: 33811811 DOI: 10.1016/j.celrep.2021.108959] [Cited by in Crossref: 27] [Cited by in F6Publishing: 38] [Article Influence: 27.0] [Reference Citation Analysis]
12 Farhat Ullah M, Ali Y, Ramzan Khan M, Ullah Khan I, Yan B, Ijaz Khan M, Malik MY. A review of COVID-19: Treatment Strategies and CRISPR/Cas9 gene editing technology approaches to the coronavirus disease. Saudi J Biol Sci 2021. [PMID: 34658640 DOI: 10.1016/j.sjbs.2021.10.020] [Reference Citation Analysis]
13 Katayama M, Uemura Y. Therapeutic Effects of Mutian® Xraphconn on 141 Client-Owned Cats with Feline Infectious Peritonitis Predicted by Total Bilirubin Levels. Vet Sci 2021;8:328. [PMID: 34941855 DOI: 10.3390/vetsci8120328] [Reference Citation Analysis]
14 Hu CJ, Chang WS, Fang ZS, Chen YT, Wang WL, Tsai HH, Chueh LL, Takano T, Hohdatsu T, Chen HW. Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus. Sci Rep 2017;7:13043. [PMID: 29026122 DOI: 10.1038/s41598-017-13316-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
15 Miyamoto R, Kurita S, Tani H, Kobayashi M, Sugiura S, Shigihara K, Sato Y, Tanaka Y, Tamura K, Bonkobara M. Establishment and characterization of a cell line from a feline histiocytic sarcoma. Vet Immunol Immunopathol 2018;201:72-6. [PMID: 29914686 DOI: 10.1016/j.vetimm.2018.05.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Ghosh S, Malik YS. Drawing Comparisons between SARS-CoV-2 and the Animal Coronaviruses. Microorganisms 2020;8:E1840. [PMID: 33238451 DOI: 10.3390/microorganisms8111840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Evans JP, Liu SL. Role of host factors in SARS-CoV-2 entry. J Biol Chem 2021;297:100847. [PMID: 34058196 DOI: 10.1016/j.jbc.2021.100847] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
18 de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ. Host Factors in Coronavirus Replication. Curr Top Microbiol Immunol. 2018;419:1-42. [PMID: 28643204 DOI: 10.1007/82_2017_25] [Cited by in Crossref: 106] [Cited by in F6Publishing: 144] [Article Influence: 35.3] [Reference Citation Analysis]